PathGen Achieves Funding From East Ventures: Increase Early Detection Technology For Various Diseases

Illustration of PCR technology from PathGen (photo: PathGen)

JAKARTA - PathGen or PathGen Diagnostic Technology, a health biotechnology startup based in Indonesia focused on molecular testing solutions, received funding from East Ventures and the Indonesian Royal Group.

This funding will be allocated for the development of several main areas, such as Research and Development (R&D), the use of technology, market expansion, and so on.

"We are confident that this funding will support our mission to improve the quality of life of the community by democratizing molecular testing solutions that are in accordance with the local context," said Susanti, Co-Founder and Chief Executive Officer PathGen.

PathGen was founded in 2020 by Dr. Susanti (Co-Founder and Chief Executive Officer) and dr. Michael Rampangilei (Co-Founder and Chief Operating Officer) who joined in 2023.

PathGen comes with a vision to democratize genomic solutions in low- and middle-income countries by providing affordable molecular diagnostic tools to detect cancer and various other diseases in Indonesia.

As a solution, PathGen provides a accessible and reliable molecular diagnostic solution to identify risks based on family history, determine prognosis (precipitation for a disease), and predict treatment responses.

PathGen is also developing a series of molecular genetic testing tools for various types of cancer, such as colorectal, lung, cervical, and nasopharyngeal cancer.

To facilitate smooth testing and increase adoption in the Indonesian market, this test kit will mostly be PCR-based. The use of PCR technology will provide a feasible comprehensive testing solution both technically and financially with existing infrastructure and consider price constraints in the Indonesian market.

PathGen is also developing molecular diagnostics through the development of cutting-edge technology such as Next-generation sequencing (NGS) for cancer and other diseases.